When is preservative-free therapy of glaucoma needed and advisable?
https://doi.org/10.21516/2072-0076-2021-14-3-25-31
Abstract
Purpose: to estimate the demand for preservative-free medical therapy of glaucoma in real clinical practice as part of the analysis of the compliance of specialized medical care of glaucoma patients and the approved clinical guidelines.
Material and methods. Head non-staff ophthalmologists in 34 regions of Russia were surveyed to find out the share of patients with a newly diagnosed primary open-angle glaucoma; systemic contraindications; diseases of ocular surface tissues; using combination therapy if monotherapy proves ineffective. Also, we analyzed the current annual need for glaucoma treatment drugs in Russia and estimated the expected need for these drugs.
Results. The survey showed that, on average, (1) 64.35 % of glaucoma patients are prescribed monotherapy; (2) in the presence of systemic contraindications, nonselective beta-blockers are avoided in 85 % of cases; (3) ca. 53 % of glaucoma patients require preservative-free therapy; (4) almost 61 % of patients for whom monotherapy proved ineffective are prescribed combination therapy. As shown by calculated annual and projected demand for antiglaucomatous drugs in 2020, the leading position is taken by timolol (43.96 %), followed by dorzolamide (38.04 %), and tafluprost (11.93 %). Diseases of the ocular surface in glaucoma patients with glaucoma averaged 52.6 % in the surveyed regions.
Conclusion. The actual demand for preservative-free therapy in clinical practice in the analyzed regions is higher than the annual and predicted need as it is required by about 54% of all patients with glaucoma. Further epidemiological, pharmacological and economic studies of ocular surface disease incidence in patients with glaucoma and of the demand for preservative-free therapy are required in order to solve the issue of drug supply in regions of Russia.
About the Authors
T. N. Malishevskaya
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Dr. of Med. Sci., head, department of analytics
14/19, Sadovaya Chernogryazskaya St., Moscow, 105062, Russia
S. Yu. Petrov
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Dr. of Med. Sci., head, department of glaucoma
14/19, Sadovaya Chernogryazskaya St., Moscow, 105062, Russia
S. M. Kosakyan
Helmholtz National Medical Research Center of Eye Diseases
Russian Federation
Russian Federation
Cand. of Med. Sci., ophthalmologist, department of glaucoma
14/19, Sadovaya Chernogryazskaya St., Moscow, 105062, Russia
S. A. Vlasova
Regional Ophthalmologic Clinic;
West Siberian Institute of postgraduate medical education
Russian Federation
Russian Federation
ophthalmologist, out-patient department of glaucoma, assistant professor, chair of ophthalmology and optometry
118/1, Kholodilnaya St., Tyumen, 625048, Russia
5/11, Prokopiya Artamonova St., Tyumen, 625051, Russia
References
1. Neroev V.V., Kiseleva O.A., Bessmertny A.M. The Main results of a multicenter study of epidemiological features of primary openangle glaucoma in Russian Federation. Russian ophthalmological journal. 2013; 3: 4–7 (in Russian).
2. Egorov E.A., Eriсhev V.P., ed. National Guidelines for Glaucoma Practitioners. Ed. 4th, rev. and ad. Moscow: GEOTAR-Media; 2019 (In Russian).
3. Tham Y.C., Li X., Wong T.Y., et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 2081–90. doi: 10.1016/j.ophtha.2014.05.013
4. Bourne R.R.A., Jonas J.B., Bron A.M., et al. Prevalence and causes of vision loss in high income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br. J. Ophthalmol. 2018; 102 (5): 575–85. doi: 10.1136/bjophthalmol-2017-311258
5. Baudouin C., Denoyer A., Desbenoit N., Hamm G., Grise A. In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis). Trans Am. Ophthalmol. Soc. 2012; 110: 40–63.
6. Baudouin C., Renard J., Nordmann J. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur. J. Ophthalmol. 2012; 23: 47–54. doi: 10.5301/ejo.5000181
7. Skalicky S.E., Goldberg I., Mc Cluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am. J. Ophthalmol. 2012; 153 (1): 1–9; e2. doi: 10.1016/j.ajo.2011.05.033
8. Pflugfelder S., Baudoin C. Chclinical measurment of ocular surface diseae in glaucoma patients. ClinOphthalmol. 2011; 5: 1575–83. doi 10.2147/opth.s 24410.
9. Leung E.W., Medeiros F.A., Weinreb R.N. Prevalence of ocular surface disease in glaucoma patients. J. Glaucoma. 2008; 17 (5): 350–5. doi 10.1097/ijg.0b013e31815c5f4f
10. Brzhevskiy V.V. Glaucoma and dry eye syndrom. Moscow; 2018 (In Russian).
11. Baudouin C., Labbe A., Liang H., Pauly A., Brignole Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010; 29 (4): 312–34. doi: 10.1016/j.preteyeres.2010.03.001
12. Bonniard A.A., Yeung J.Y., Chan C.C., Birt C.M. Ocular surface toxicity from glaucoma topical medications and associated preservatives such as benzalkonium chloride (BAK). Expert Opin. Drug Metab. Toxicol. 2016; 12 (11): 1279–89. doi: 10.1080/17425255.2016.1209481
13. Datta S., Baudouin C. The eye drop preservative benzalkonium chloride potently induces mitochondrial dysfunction and preferentially affects LHON mutant cells. Invest. Ophthalmol. Vis. Sci. 2017; 58: 2406–12. doi:10.1167/ iovs.16-20903
14. Broadway D.C., Grierson I., O’Brien C., Hitchings R.A. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch. Ophthalmol. Chic. 1994; 112 (11): 1446–54. https://doi.org/10.1001/archopht.1994.01090230060021
15. Baudouin C. Ocular surface and external filtration surgery: mutual relationships. Dev Ophthalmol. 2017; 59: 67–79. doi: 10.1159/000458487
16. Broadway D.C., Chang L.P. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. J. Glaucoma. 2001; 10 (3): 237–49. doi: 10.1097/00061198-200106000-00017
17. Chamard С., Larrieu S., Baudouin C., et al. Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016. Acta Ophthalmol. 2020: 98 (7): e876–e81. doi: 10.1111/aos.14410
18. Nagornova Z.M., Kuroyedov A.V., Petrov S.Yu., et al. The effect of topical hypotensive therapy on ocular surface and glaucoma surgery outcomes in patients with primary open-angle glaucoma. Natsional’nyi zhurnal glaukoma. 2019; 18 (4): 96–107 (In Russian). https://doi.org/10.25700/NJG.2019.04.08
19. Boimer C., Birt C.M. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J. Glaucoma. 2013; 22 (9): 730–5. doi: 10.1097/IJG.0b013e31825af67d
20. Meloni M., Pauly A., Servi B.D., Varlet B.L., Baudouin C. Occludin gene expression as an early in vitro sign for mild eye irritation assessment. Toxicol in Vitro Int. 2010; 24 (1): 276–85 doi: 10.1016/j.tiv.2009.08.016
21. Meloni M., Balzaretti S., Ceriotti L. Medical devices biocompatibility assessment on HCE: Evidences of delayed cytotoxicity of preserved compared to preservative free eye drops. Regul. Toxicol. Pharmacol. 2019; 106: 81–9. doi: 10.1016/j.yrtph.2019.04.022
22. Steven D.W., Alaghband P., Lim K.Sh. Preservatives in glaucoma medication. Br. J. Ophthalmol. 2018; 102: 1497–503. doi:10.1136/bjophthalmol-2017-311544
23. Hamard P., Valtot F., Sourdille P., Bourles-Dagonet F., Baudouin C. Confocal microscopic examination of trabecular meshwork removed during ab externo trabeculectomy. Br. J. Ophthalmol. 2002; 86 (9): 1046–52. doi: 10.1136/bjo.86.9.1046
24. Beasley R., Burgess C., Holt S. Call for worldwide withdrawal of benzalkonium chloride from nebulizer solutions. J. Allergy Clin. Immunol. 2001; 107 (2): 222–3. doi: 10.1067/mai.2001.112941
25. Jaenen N., Baudouin C., Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 2007; 17 (3): 341–9. doi: 10.1177/112067210701700311
26. Detry-Morel M. Side effects of glaucoma medications Bull. Soc. Belge Ophtalmol. 2006; 299: 27–40.
27. Ichijima H., Petroll W.M., Jester J.V., Cavanagh H.D. Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea. 1992; 11 (3): 221–5.
28. Pauly A., Meloni M., Brignole-Baudouin F., Warnet J.M., Baudouin C. Multiple endpoint analysis of the 3D-reconstituted corneal epithelium after treatment with benzalkonium chloride: early detection of toxic damage. Invest. Ophthalmol. Vis. Sci. 2009; 50 (4): 1644–52. doi: 10.1167/iovs.08-2992
29. Burstein N.L. Preservative alteration of corneal permeability in humans and rabbits. Invest. Ophthalmol. Vis. Sci. 1984; 25 (12): 1453–7.
30. Munoz Negrete F.J., Lemij H.G., Erb C. Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction. Clin. Ophthalmol. 2017; 11: 557–66. doi: 10.2147/OPTH.S126042
31. Economou M.A., Laukeland H.K., Grabska-Liberek I., Rouland J-F. Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real life FREE study. Clin. Ophthalmol. 2018; 12: 2399–2407. doi: 10.2147/OPTH.S176605
32. Baudouin C., Liang H., Hamard P., et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008; 115 (1): 109–15. doi: 10.1016/j.ophtha.2007.01.036
33. Januleviciene I., Derkac I., Grybauskiene L., et al. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin. Ophthalmol. 2012; 6: 103–9. doi: 10.2147/OPTH.S28104
34. Hommer A., Schmidl D., Kromus M., et al. Effect of changing from preserved prostaglandins to preservative-free tafluprost in patients with glaucoma on tear film thickness. Eur. J. Ophthalmol. 2018; 28 (4): 385–92. doi: 10.1177/1120672117753703
35. Stevens A.M., Kestelyn P.A., De Bacquer D., Kestelyn P.G. Benzalkonium chloride induces anterior chamber inflammation in previously untreated patients with ocular hypertension as measured by flare meter: a randomized clinical trial. Acta Ophthalmol. (Copenh). 2012; 90 (3): e221–4. doi: 10.1111/j.1755-3768.2011.02338.x
36. Pisella P.J., Pouliquen P., Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br. J. Ophthalmol. 2002; 86 (4): 418–23. doi: 10.1136/bjo.86.4.418
37. Rouland J.F.Etude CARAT: acceptabilitéd’un collyre bêtabloquant sans conservateur dans le traitement du glaucome. [Acceptability of preservative-free beta-blocker eye drops in the treatment of glaucoma]. Réflexions Ophtalmologiques. 2011; 150: 43–6 (In French).
38. Van Went C., Brasnu E., Hamard P., Baudouin C., Labbé A. [The influence of ocular surface diseases in the management of glaucoma]. J. Fr. Ophtalmol. 2011; 34 (4): 230–7 (In French). doi: 10.1016/j.jfo.2010.11.010
39. Levrat F., Pisella P.J., Baudouin C. [Clinical tolerance of antiglaucoma eyedrops with and without a preservative. Results of an unpublished survey in Europe]. J. Fr. Ophtalmol. 1999; 22 (2): 186–91 (in French).
40. Pisella P.J., Lala E., Parier V., Brignole F., Baudouin C. [Effect of preservatives on the conjunctiva: a comparative study of beta-blocker eye drops with and without preservatives in glaucoma patients]. J. Fr. Ophtalmol. 2003; 26 (7): 675–9 (In French).
41. Pisella P.J., Debbasch C., Hamard P. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Invest. Ophthalmol. Vis. Sci. 2004; 45 (5): 1360–8. doi: 10.1167/iovs.03-1067
42. Leske M.C., Heijl A., Hyman L., Bengtsson B., Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr. Opin. Ophthalmol. 2004; 15 (2): 102–6. doi: 10.1097/00055735-200404000-00008
43. NHMRC Guidelines for the screening, prognosis, diagnosis, management and prevention of glaucoma 2010. Common wealth of Australia 2010: 18.
44. American Academy of Ophthalmology Primary Open-Angle Glaucoma Preferred Practice Pattern Guidelines. American Academy of Ophthalmology. Published by Elsevier Inc. 2016: 64–5.
45. Glaucoma: diagnosis and management. NICE guideline 2017. Available at: https://www.nice.org.uk/guidance/ng81/resources/glaucoma-diagnosis-and-managementpdf-1837689655237
46. European Glaucoma Society, 4th Edition. Savona: PubliComm; 2020.
47. All India ophthalmological society: Guidelines for Medical Management of Glaucoma. 2011: 21.
48. Guidelines for primary open angle glaucoma 2020 (16.02.2021). Approved by Russian Ministry of Health (In Russian). Available at: https://organum-visus.ru/library/newspdf/klinicheskie-rekomendacii-glaukoma-poug-2020
49. Thygesen J. Glaucoma therapy: preservative-free for all. Clinical Ophthalmology. 2018; 12: 707–17 doi: 10.2147/OPTH.S150816
50. Barton K., Hitchings R.A. Medical Treatment of Glaucoma. Springer Nature Switzerland AG. Budenz D. (Ed.). 2013. Available at: https://www.springer.com/gp/book/9781858734309
51. Casper D.S., Cioffi G.A., eds. The Columbia Guide to Basic Elements of Eye Care. 2019. Avaible at: https://doi.org/10.1007/978-3-030-10886-1_19
52. IQVIA. Retail Sales Monitoring. March, 2020 (In Russian). Available at: https://www.iqvia.com2020_v07-hq.pdf]
Review
For citations:
Malishevskaya T.N., Petrov S.Yu., Kosakyan S.M., Vlasova S.A. When is preservative-free therapy of glaucoma needed and advisable? Russian Ophthalmological Journal. 2021;14(3):25-31. (In Russ.) https://doi.org/10.21516/2072-0076-2021-14-3-25-31
Views:
884
Email this article 